JMP Securities Reiterates Market Outperform on Integra Lifesciences, Maintains $55 Price Target
JMP Securities Reiterates Market Outperform on Integra Lifesciences, Maintains $55 Price Target
摩根大通證券重申Integra Lifesciences的市場表現跑贏大盤，維持55美元的目標股價
JMP Securities analyst David Turkaly reiterates Integra Lifesciences (NASDAQ:IART) with a Market Outperform and maintains $55 price target.
JMP Securities分析師戴維·圖爾卡利重申，Integra Lifesciences（納斯達克股票代碼：IART）大盤跑贏大盤，維持55美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。